We're taking a big picture perspective across neuromuscular diseases to uncover breakthroughs for treatments and cures.Impact in 2016
The power in our research approach is that we can often apply learnings from one disease to progress in others to bring urgently-needed answers to our families. We also help spread scientific knowledge and train the next generation of scientific leaders by funding national and international research conferences, clinical research training grants and career development grants.
MDA in June announced the award of a clinical research network grant (CRNG) to Michael Benatar, M.D., Ph.D., at the University of Miami Miller School of Medicine in Florida, and Jonathan Katz, M.D., at California Pacific Medical Center in San Francisco, to support the Clinical Procedures To Support Research (CAPTURE) project, which aims to implement the “ALS Toolkit” within the Epic Electronic Health Record System.
Systemic identification of causal mutations? Mitochondrial apoptosis mediator? Epigenetic silencing? MDA’s 2017 Scientific Conference got off to a quick start Monday morning, with platform presentations covering a variety of topics delivered by the world’s preeminent neuromuscular disease researchers.
All MDA grants have the same basic goal: moving promising treatments through the “drug development pipeline,” from early discoveries in the lab, to clinical trials, to actual therapies that can be prescribed in the clinic.
Our new Clinical Trials Finder Tool guides you through a series of questions to pinpoint trials for you or a loved one. In just a few minutes, you can gain access to vital research opportunities nationwide.
Following the unprecedented approval of three drugs in six months to treat neuromuscular diseases, we're pushing for more progress with $7 million in new research funding.
We’re taking a big picture approach to accelerating treatments and cures for muscular dystrophy, ALS and related diseases.
MDA research staff oversee grants programs and provide guidance on scientific and medical matters for MDA. Staff members interact with federal agencies, international neuromuscular disease partners, drug development groups and pharmaceutical companies, as well as with patient advocacy groups and other neuromuscular disease stakeholders. In addition, they manage basic and translational research portfolios relating to the diseases in MDA's program.
Our trained specialists are here to provide one-on-one support for every part of your journey. Send a message below or call us at 800-572-1717. If you live outside the U.S., we may be able to connect you to muscular dystrophy groups in your area, but MDA services are only available in the U.S.